Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study
Dr. Guoliang Yu, the companys Co-Founder, Chairman and CEO said that: APL-102 is a small molecule multi-kinase inhibitor developed by us.
- Dr. Guoliang Yu, the companys Co-Founder, Chairman and CEO said that: APL-102 is a small molecule multi-kinase inhibitor developed by us.
- APL-102 may not only be used as a single agent to treat patients, but also has a potential of being co-administered with immunotherapy and other treatments as a combination therapy.
- APL-102 is an oral, multi kinase inhibitor (mKi) targeting several key oncogenic drivers.
- Apollomics owns the global clinical development, production and commercial sales rights of APL-102.